MCRC public
[search 0]
More

Download the App!

show episodes
 
Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location. To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC). This non-certified educational series is sponsored by Lilly. Content for this series is produced a ...
 
Loading …
show series
 
Featuring Dr. Dr. Marcus Butler, Dr. Michael Smylie, and Dr. Jason Luke Trials Discussed: Metastatic/Advanced Melanoma: COMBI-i Trial, LEAP-004 and SECOMBIT Adjuvant Trials in Melanoma: KEYNOTE 054 and CheckMate 238 Metastatic/Advanced Melanoma: Local Therapy in Solitary Melanoma, NIVO+IPI vs NIVO and ILLUMINATE-204 Non-Melanoma Skin Cancer: PD1 Bl…
 
Featuring Dr. Barbara Melosky, Dr. Parneet Cheema, and Dr. Peter Ellis. Trials Discussed: Presidential Symposiums: CROWN, ADAURA, and Lung Art Metastatic NSCLC: ZENITH20 and TAK-788 Metastatic NSCLC & EGFR Drug Conjugates: Amivantamab & Lazertinib and Patritumab Deruxtecan Stage III NSCLC: 4-year survival of PACIFIC trial Neoadjuvant Trials: durval…
 
Featuring Dr. Srikala Sridhar, Dr. Sebastien Hotte, and Dr. Petros Grivas Trials Discussed: Bladder Cancer: KEYNOTE-361, DANUBE and TROPHY-U-01 Cohort 1 Kidney/Prostate Cancer: CheckMate-9ER and COSMIC Prostate Cancer: IPATential150, PROfound and STAMPEDE This podcast has been made available through sponsorship from BMS and Ipsen.…
 
Featuring: Dr. Bruce Colwell (Chair) Dr. Rachel Goodwin This podcast has been made available through unrestricted sponsorship support from Amgen. Learning Objectives: Discuss the evidence that supports current mCRC treatment recommendations Discuss treatment attrition and how it may impact clinical practice Describe the challenges to implement evid…
 
This episode features Dr. Richard LeBlanc, Dr. Darrell White, and Dr. Julie Stakiw. This program was made possible by unrestricted sponsorship support from Amgen. Trials Discussed: 1. First-line for transplant-eligible myeloma: STaMINA & GMMG-HD6: 00:02:02 2. First-line for non-transplant-eligible (or transplant-deferred) myeloma: ENDURANCE, SWOG 1…
 
This episode features Dr. Michael Smylie, Dr. Marcus Butler, and Dr. Jason Luke. This program was made possible by unrestricted sponsorship support from Merck. Trials Discussed: Advanced Melanoma: LN-144: 00:01:03 Adjuvant Melanoma: COMBI-AD & EORTC 1325-MG/KEYNOTE 054: 00:10:41 Metastatic Melanoma: COMBO IMMUNOTHERAPY (NIVOLIMAB + IPILUMAB): 00:28…
 
This episode features Dr. Gwyn Bebb, Dr. Philippe Bedard and Dr. Daniel Renouf. Trials Discussed: MSI-H Tumors: KEYNOTE-177 & Pembrolizumab Monotherapy in MSI-H Pts: 00:01:15 NTRK Tumors: NTRK-FP Solid Tumors - Integrated Analysis & Larotrectinib in Pts with TRK Fusion: 00:13:39 RET Fusion+ Solid Tumors: BLU-667 in RET Fusion+ Solid Tumors: 00:22:4…
 
This episode features Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Jeffrey Rothenstein. This program was made possible by unrestricted sponsorship support from AstraZeneca. Trials Discussed: Adjuvant NSCLC: CTONG 1104 & ADAURA: 00:01:11 Metastatic NSCLC: NEJ026, CONCURRENT OSIMERTINIB/GEFITINIB, JNJ-61186372, OSIMERTINIB 160MG, Poziotinib in pre…
 
This episode features Dr. Scott Berry, Dr. Sharlene Gill, and Dr. Marc Peeters. This program was made possible by unrestricted sponsorship support from Merck. Trials Discussed: Metastatic Colorectal Cancer: KEYNOTE-177 & PANDA: 00:01:16 Adjuvant Colorectal Cancer: IDEA, CALGB/SWOG 80702 & JCOG0603: 00:13:32 Rectal Cancer: RAPIDO, UNICANCER PRODIGE …
 
This episode features Dr. Daniel Heng, Dr. Srikala Sridhar and Dr. Kim Chi. This program was made possible by unrestricted sponsorship support from Ipsen and Merck. Trials Discussed: Bladder Cancer: JAVELIN & IMvigor010: 00:01:22 Kidney Cancer: KEYNOTE-426 & OMNIVORE: 00:16:45 Prostate Cancer: CONDOR & TheraP: 00:38:48 Prostate Cancer: HERO, SPARTA…
 
This episode features Dr. Heather McArthur, Dr. Christine Brezden-Masley, and Dr. Christine Simmons. This program was made possible by unrestricted sponsorship support from Mylan. Trials Discussed: De Novo Stage IV Breast Cancer: ECOG-ACRIN (E2108) : 00:01:00 HER2+ Breast Cancer, Adjuvant: KATHERINE & KAITLIN: 00:13:18 HER2+ Breast Cancer, Neoadjuv…
 
Guest: Putao Cen, MD Tune in to hear Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School, discussing the clinical presentations of tumor sidedness in colorectal cancer patients and how it affects diagnosis, prognosis, and treatment.…
 
Guest: Putao Cen, MD Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.…
 
Guest: Putao Cen, MD When a patient with metastatic colorectal cancer experiences adverse events like complete obstruction and tumor perforations, it can further complicate an already-difficult disease to manage. That’s why Dr. Putao Cen is here to reveal his key strategies in managing these and other adverse events in metastatic colorectal cancer.…
 
Host: John J. Russell, MD Guest: Axel Grothey, MD Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal ca…
 
Host: John J. Russell, MD Guest: Axel Grothey, MD Since biomarker testing can aid in the creation of individualized treatment plans, Dr. Axel Grothey is here to provide his perspective on the current state of biomarker testing for colorectal cancer and how we can increase biomarker testing practices at the time of diagnosis.…
 
In this episode, we'll listen to Dr. Scott Berry, Dr. Marc Peeters and Dr. Sharlene Gill, discuss the important trials presented at ASCO 2019. 08:20 - Apact Trial 16:35 - Phase 3 Trial of 1st Line Chemo vs Pembrolizumab vs Chemo + Pembrolizumab for Metastatic Gastric CA 24:15 - Phase 3 Trial of 2nd Line Pembrolizumab vs Placebo for HCC 30:26 - ABC-…
 
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best …
 
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best …
 
In this episode we’ll listen in on a conversation that Dr. Sunil Verma, Medical Director of the Tom Baker Cancer Centre, Dr. Sara Tolaney Associate Director of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, and Dr. Christine Simmons Medical Oncologist with the British Columbia Cancer Agency, had at the 2019 Best …
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login